5-bromo-N4-2-pyridinyl-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-2,4-pyrimidinediamine | 719312-02-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-bromo-N4-2-pyridinyl-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-2,4-pyrimidinediamine
• 英文别名: OICR0007450；5-Bromo-N4-pyridin-2-yl-N2-[3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]-pyrimidine-2,4-diamine；5-bromo-N4-(pyridin-2-yl)-N2-(3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl)pyrimidine-2,4-diamine；5-bromo-4-N-pyridin-2-yl-2-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine
• CAS: 719312-02-4
• 化学式: C₂₂H₂₀BrN₇
• 分子量: 462.352
• InChiKey: SNUDKENUHIKEBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  90.6
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME
  申请人：Cohen Stephen Michael

  公开号：US20140227289A1

  公开（公告）日：2014-08-14

  The present invention relates to a method of treating or preventing insulin resistance syndrome in an animal body by administering an inhibitor of protein kinase RNA-like endoplasmic reticulum kinase (PERK) gene, or a functional variant thereof, or an inhibitor of PERK protein or a functional variant thereof or a method of reducing activity of transcription factors of the FOXO family (Foxo 1, 3a, 4 and 6) by administering an inhibitor of protein kinase RNA-like endoplasmic reticulum kinase (PERK) gene, or a functional variant thereof, or an inhibitor of PERK protein or a functional variant thereof. The present invention also relates to different compounds and methods for using PERK gene or PERK protein.

  本发明涉及通过给动物体内注射蛋白激酶RNA样内质网激酶（PERK）基因的抑制剂或其功能变体，或PERK蛋白或其功能变体的抑制剂，或通过给动物体内注射蛋白激酶RNA样内质网激酶（PERK）基因的抑制剂或其功能变体，或PERK蛋白或其功能变体的抑制剂来减少FOXO家族转录因子（Foxo 1、3a、4和6）活性的方法，用于治疗或预防动物体内的胰岛素抵抗综合征。本发明还涉及不同的化合物和使用PERK基因或PERK蛋白的方法。
• Pyrimidine derivatives for the treatment of abnormal cell growth
  申请人：Kath Charles John

  公开号：US20050256111A1

  公开（公告）日：2005-11-17

  The present invention relates to a compound of the formula 1 wherein R 1 -R 4 and Ar are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

  本发明涉及一种式子为1的化合物，其中R1-R4和Ar的定义如本文所述。这种新型嘧啶衍生物在哺乳动物中治疗异常细胞生长，如癌症方面具有用处。本发明还涉及一种使用这种化合物治疗哺乳动物，特别是人类异常细胞生长的方法，以及包含这种化合物的制药组合物。
• Compound for the treatment of abnormal cell growth
  申请人：Pfizer Inc

  公开号：US20040220177A1

  公开（公告）日：2004-11-04

  The invention relates to compounds of the formula 1 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , n, A and B are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  本发明涉及公式11的化合物，以及其药物可接受的盐、前药和溶剂化物，其中R1、R2、R3、R4、R5、n、A和B的定义如本文所述。本发明还涉及通过给予公式1的化合物治疗哺乳动物异常细胞生长的方法，并涉及用于治疗此类疾病的制药组合物，其中包含公式1的化合物。本发明还涉及制备公式1的化合物的方法。
• PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
  申请人：Pfizer Products Inc.

  公开号：EP1578732A2

  公开（公告）日：2005-09-28
• PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
  申请人：Pfizer Products Incorporated

  公开号：EP1758887A1

  公开（公告）日：2007-03-07